<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antipsychotics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i363.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i363.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i363.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i916.htm" title="Previous: Trospium">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1209.htm" title="Next: Asenapine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i363">Antipsychotics</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antipsychotics</b>
          has the following interaction information:
        </p><div>Increased risk of toxicity with myelosuppressive drugs</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i2.htm" name="_2">ACE Inhibitors</a></td><td>enhanced hypotensive effect when  antipsychotics given with ACE inhibitors </td><td></td></tr><tr><td><a href="41001i20.htm" name="_20">Alcohol</a></td><td>increased sedative effect when  antipsychotics given with alcohol </td><td></td></tr><tr><td><a href="41001i26.htm" name="_26">Alpha-blockers</a></td><td>enhanced hypotensive effect when  antipsychotics given with alpha-blockers </td><td></td></tr><tr><td><a href="41001i555.htm" name="_555">Amantadine</a></td><td>increased risk of extrapyramidal side-effects when  antipsychotics given with amantadine </td><td></td></tr><tr><td><a href="41001i39.htm" name="_39">Anaesthetics, General</a></td><td class="cBV"><b>enhanced hypotensive effect when  antipsychotics given with general anaesthetics </b></td><td><i>See also</i> Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="6559.htm#_6559.1">section 15.1</a>



</td></tr><tr><td><a href="41001i107.htm">Angiotensin-II Receptor Antagonists</a></td><td>enhanced hypotensive effect when  antipsychotics given with angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i116.htm">Anti-arrhythmics</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  antipsychotics that prolong the QT interval given with anti-arrhythmics that prolong the QT interval</b></td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td class="cBV"><b> antipsychotics increase plasma concentration of tricyclics—possibly increased risk of ventricular arrhythmias</b></td><td></td></tr><tr><td><a href="41001i276.htm" name="_276">Antiepileptics</a></td><td class="cBV"><b> antipsychotics antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td>increased sedative effect when  antipsychotics given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i430.htm" name="_430">Apomorphine</a></td><td> antipsychotics antagonise effects of apomorphine </td><td></td></tr><tr><td><a href="41001i1168.htm" name="_1168">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  antipsychotics that prolong the QT interval given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  antipsychotics advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i1009.htm" name="_1009">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  antipsychotics that prolong the QT interval given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i556.htm" name="_556">Bromocriptine</a></td><td> antipsychotics antagonise hypoprolactinaemic and antiparkinsonian effects of bromocriptine </td><td></td></tr><tr><td><a href="41001i557.htm" name="_557">Cabergoline</a></td><td> antipsychotics antagonise hypoprolactinaemic and antiparkinsonian effects of cabergoline </td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>enhanced hypotensive effect when  antipsychotics given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>effects of  antipsychotics possibly enhanced by cimetidine </td><td></td></tr><tr><td><a href="41001i1180.htm">Histamine</a></td><td> antipsychotics theoretically antagonise effects of histamine—manufacturer of histamine advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i558.htm" name="_558">Levodopa</a></td><td> antipsychotics antagonise effects of levodopa </td><td></td></tr><tr><td><a href="41001i942.htm">Memantine</a></td><td>effects of  antipsychotics possibly reduced by memantine </td><td></td></tr><tr><td><a href="41001i97.htm" name="_97">Methadone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  antipsychotics that prolong the QT interval given with methadone </b></td><td></td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td>enhanced hypotensive effect when  antipsychotics given with methyldopa (also increased risk of extrapyramidal effects)</td><td></td></tr><tr><td><a href="41001i613.htm" name="_613">Metoclopramide</a></td><td>increased risk of extrapyramidal side-effects when  antipsychotics given with metoclopramide </td><td></td></tr><tr><td><a href="41001i85.htm">Opioid Analgesics</a></td><td>enhanced hypotensive and sedative effects when  antipsychotics given with opioid analgesics </td><td></td></tr><tr><td><a href="41001i659.htm" name="_659">Pergolide</a></td><td> antipsychotics antagonise effects of pergolide </td><td></td></tr><tr><td><a href="41001i881.htm" name="_881">Pramipexole</a></td><td>avoidance of  antipsychotics advised by manufacturer of pramipexole (antagonism of effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  antipsychotics possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i686.htm" name="_686">Ropinirole</a></td><td>avoidance of  antipsychotics advised by manufacturer of ropinirole (antagonism of effect)</td><td></td></tr><tr><td><a href="41001i1066.htm" name="_1066">Rotigotine</a></td><td>avoidance of  antipsychotics advised by manufacturer of rotigotine (antagonism of effect)</td><td></td></tr><tr><td><a href="41001i1067.htm" name="_1067">Sodium Oxybate</a></td><td> antipsychotics possibly enhance effects of sodium oxybate </td><td></td></tr><tr><td><a href="41001i690.htm" name="_690">Sympathomimetics</a></td><td> antipsychotics antagonise hypertensive effect of sympathomimetics </td><td></td></tr><tr><td><a href="41001i733.htm">Tetrabenazine</a></td><td>increased risk of extrapyramidal side-effects when  antipsychotics given with tetrabenazine </td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td>increased risk of convulsions when  antipsychotics given with tramadol </td><td></td></tr></tbody></table><p><b>Asenapine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>plasma concentration of  asenapine possibly increased by fluvoxamine </td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td> asenapine possibly increases plasma concentration of paroxetine </td><td></td></tr></tbody></table><p><b>Paliperidone</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  paliperidone reduced by carbamazepine </td><td></td></tr></tbody></table><p><b>Aripiprazole</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



















<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by atazanavir (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  aripiprazole reduced by carbamazepine—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  aripiprazole possibly reduced by efavirenz—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by fluoxetine (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by fosamprenavir (reduce dose of aripiprazole)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by indinavir (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by itraconazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>metabolism of  aripiprazole inhibited by ketoconazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by lopinavir (reduce dose of aripiprazole)</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by nelfinavir (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b>plasma concentration of  aripiprazole possibly reduced by nevirapine—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by paroxetine (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  aripiprazole possibly reduced by phenobarbital—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  aripiprazole possibly reduced by phenytoin—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>plasma concentration of  aripiprazole possibly reduced by rifabutin—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  aripiprazole possibly reduced by rifampicin—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by ritonavir (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>metabolism of  aripiprazole possibly inhibited by saquinavir (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  aripiprazole possibly reduced by St John's wort—increase dose of aripiprazole</b></td><td></td></tr></tbody></table><p><b>Amisulpride</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amisulpride given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amisulpride given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td class="cBV"><b>risk of ventricular arrhythmias with  amisulpride increased by hypokalaemia caused by diuretics </b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amisulpride given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amisulpride given with erythromycin—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i558.htm">Levodopa</a></td><td>manufacturer of  amisulpride advises avoid concomitant use of levodopa (antagonism of effect)</td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amisulpride given with methadone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amisulpride given with pentamidine isetionate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amisulpride given with sotalol </b></td><td></td></tr></tbody></table><p><b>Clozapine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><div>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

































<tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td>possible increased antimuscarinic side-effects when  clozapine given with tricyclics </td><td></td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>increased risk of antimuscarinic side-effects when  clozapine given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i405.htm">Benzodiazepines</a></td><td class="cBV"><b>serious adverse events reported with concomitant use of  clozapine and benzodiazepines (causality not established)</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>metabolism of  clozapine accelerated by carbamazepine (reduced plasma concentration), also avoid concomitant use of drugs with substantial potential for causing agranulocytosis</b></td><td></td></tr><tr><td><a href="41001i158.htm">Chloramphenicol</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with chloramphenicol (increased risk of agranulocytosis)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>effects of  clozapine possibly enhanced by cimetidine </td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td>plasma concentration of  clozapine increased by ciprofloxacin </td><td></td></tr><tr><td><a href="41001i233.htm">Citalopram</a></td><td>plasma concentration of  clozapine possibly increased by citalopram (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i500.htm">Cytotoxics</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with cytotoxics (increased risk of agranulocytosis)</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  clozapine possibly increased by erythromycin (possible increased risk of convulsions)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b>increased risk of arrhythmias when  clozapine given with flecainide </b></td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>plasma concentration of  clozapine increased by fluoxetine </b></td><td></td></tr><tr><td><a href="41001i389.htm">Flupentixol</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with depot formulation of flupentixol as cannot be withdrawn quickly if neutropenia occurs</b></td><td></td></tr><tr><td><a href="41001i380.htm">Fluphenazine</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with depot formulation of fluphenazine as cannot be withdrawn quickly if neutropenia occurs</b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>plasma concentration of  clozapine increased by fluvoxamine </b></td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with depot formulation of haloperidol as cannot be withdrawn quickly if neutropenia occurs</b></td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>increased risk of extrapyramidal side-effects and possibly neurotoxicity when  clozapine given with lithium </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> clozapine possibly increases CNS effects of MAOIs </b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>plasma concentration of  clozapine possibly reduced by omeprazole </td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td class="cBV"><b>plasma concentration of  clozapine increased by paroxetine </b></td><td></td></tr><tr><td><a href="41001i658.htm">Penicillamine</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with penicillamine (increased risk of agranulocytosis)</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  clozapine possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>metabolism of  clozapine accelerated by phenytoin (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i378.htm">Pipotiazine</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with depot formulation of pipotiazine as cannot be withdrawn quickly if neutropenia occurs</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  clozapine possibly reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i368.htm">Risperidone</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with depot formulation of risperidone as cannot be withdrawn quickly if neutropenia occurs</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  clozapine increased by ritonavir (increased risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  clozapine given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td class="cBV"><b>plasma concentration of  clozapine increased by sertraline </b></td><td></td></tr><tr><td><a href="41001i203.htm">Sulfonamides</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with sulfonamides (increased risk of agranulocytosis)</b></td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td>plasma concentration of  clozapine possibly increased or decreased by valproate </td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td class="cBV"><b>plasma concentration of  clozapine increased by venlafaxine </b></td><td></td></tr><tr><td><a href="41001i390.htm">Zuclopenthixol</a></td><td class="cBV"><b>avoid concomitant use of  clozapine with depot formulation of zuclopenthixol as cannot be withdrawn quickly if neutropenia occurs</b></td><td></td></tr></tbody></table><p><b>Olanzapine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i405.htm">Benzodiazepines</a></td><td class="cBV"><b>increased risk of hypotension, bradycardia and respiratory depression when <i>intramuscular</i>  olanzapine given with <i>parenteral</i> benzodiazepines </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>metabolism of  olanzapine accelerated by carbamazepine (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td>plasma concentration of  olanzapine possibly increased by ciprofloxacin </td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>plasma concentration of  olanzapine increased by fluvoxamine </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>possible risk of toxicity when  olanzapine given with lithium </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  olanzapine reduced by ritonavir—consider increasing dose of olanzapine</td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td class="cBV"><b>increased risk of side-effects including neutropenia when  olanzapine given with valproate </b></td><td></td></tr></tbody></table><p><b>Pimozide</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





























<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>plasma concentration of  pimozide possibly increased by SSRIs (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with tricyclics—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with imidazoles—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with triazoles—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1010.htm">Aprepitant</a></td><td class="cBV"><b>avoidance of  pimozide advised by manufacturer of aprepitant </b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  pimozide possibly increased by atazanavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  pimozide advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with clarithromycin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td class="cBV"><b>risk of ventricular arrhythmias with  pimozide increased by hypokalaemia caused by diuretics (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  pimozide possibly increased by efavirenz (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  pimozide given with erythromycin—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  pimozide increased by fosamprenavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  pimozide possibly increased by indinavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with ivabradine </b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  pimozide advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with mefloquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  pimozide possibly increased by nelfinavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with phenothiazines—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with quinine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  pimozide increased by ritonavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>plasma concentration of  pimozide possibly increased by saquinavir (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with sotalol </b></td><td></td></tr><tr><td><a href="41001i371.htm">Sulpiride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with sulpiride </b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  pimozide advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  pimozide given with telithromycin—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Quetiapine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


















<tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by imidazoles—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by triazoles—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by atazanavir—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>metabolism of  quetiapine accelerated by carbamazepine (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by clarithromycin—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by darunavir—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  quetiapine increased by erythromycin—manufacturer of quetiapine advises avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by fosamprenavir—manufacturer of quetiapine advises avoid concomitant use</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by grapefruit juice—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by indinavir—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by lopinavir—manufacturer of quetiapine advises avoid concomitant use</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by nelfinavir—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>metabolism of  quetiapine accelerated by phenytoin (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by ritonavir—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by saquinavir—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td>plasma concentration of  quetiapine possibly increased by telithromycin </td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  quetiapine possibly increased by tipranavir—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td>plasma concentration of  quetiapine possibly increased by valproate </td><td></td></tr></tbody></table><p><b>Risperidone</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>metabolism of  risperidone accelerated by carbamazepine (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of depot formulation of  risperidone with clozapine as cannot be withdrawn quickly if neutropenia occurs</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td>plasma concentration of  risperidone increased by fluoxetine </td><td></td></tr><tr><td><a href="41001i718.htm">Methylphenidate</a></td><td>side-effects of  risperidone possibly increased by methylphenidate </td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td>plasma concentration of  risperidone possibly increased by paroxetine (increased risk of toxicity)</td><td></td></tr></tbody></table><p><b>Sulpiride</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  sulpiride given with amiodarone </b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  sulpiride reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  sulpiride given with disopyramide </b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  sulpiride given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  sulpiride given with <i>parenteral</i> erythromycin </b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  sulpiride given with haloperidol </b></td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>increased risk of extrapyramidal side-effects when  sulpiride given with lithium </td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  sulpiride given with pimozide </b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  sulpiride given with sotalol </b></td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  sulpiride reduced by sucralfate </td><td></td></tr></tbody></table><p><b>Phenothiazines</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

























<tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td>enhanced hypotensive effect when  phenothiazines given with adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  phenothiazines given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  phenothiazines reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td>increased risk of antimuscarinic side-effects when  phenothiazines given with tricyclics </td><td></td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>plasma concentration of  phenothiazines reduced by antimuscarinics , but risk of antimuscarinic side-effects increased</td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td>enhanced hypotensive effect when  phenothiazines given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td>enhanced hypotensive effect when  phenothiazines given with clonidine </td><td></td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td>enhanced hypotensive effect when  phenothiazines given with diazoxide </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  phenothiazines given with disopyramide </b></td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>enhanced hypotensive effect when  phenothiazines given with diuretics </td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  phenothiazines advised by manufacturer of dronedarone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  phenothiazines that prolong the QT interval given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i763.htm">Hydralazine</a></td><td>enhanced hypotensive effect when  phenothiazines given with hydralazine </td><td></td></tr><tr><td><a href="41001i14.htm">Kaolin</a></td><td>absorption of  phenothiazines possibly reduced by kaolin </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>increased risk of extrapyramidal side-effects and possibly neurotoxicity when  phenothiazines given with lithium </td><td></td></tr><tr><td><a href="41001i764.htm">Minoxidil</a></td><td>enhanced hypotensive effect when  phenothiazines given with minoxidil </td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  phenothiazines given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td>enhanced hypotensive effect when  phenothiazines given with moxonidine </td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td>enhanced hypotensive effect when  phenothiazines given with nitrates </td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  phenothiazines given with pentamidine isetionate </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  phenothiazines given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  phenothiazines given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i765.htm">Sodium Nitroprusside</a></td><td>enhanced hypotensive effect when  phenothiazines given with sodium nitroprusside </td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  phenothiazines given with sotalol </b></td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td> phenothiazines possibly antagonise hypoglycaemic effect of sulfonylureas </td><td></td></tr></tbody></table><p><b>Chlorpromazine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td>higher doses of  chlorpromazine antagonise hypotensive effect of adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>effects of  chlorpromazine possibly enhanced by cimetidine </td><td></td></tr><tr><td><a href="41001i714.htm">Dexamfetamine</a></td><td>antipsychotic effects of  chlorpromazine possibly antagonised by dexamfetamine </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> chlorpromazine possibly increases plasma concentration of haloperidol </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of both drugs reduced when  chlorpromazine given with phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> chlorpromazine possibly increases or decreases plasma concentration of phenytoin </td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td class="cBV"><b>plasma concentration of both drugs may increase when  chlorpromazine given with propranolol </b></td><td></td></tr></tbody></table><p><b>Fluphenazine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of depot formulation of  fluphenazine with clozapine as cannot be withdrawn quickly if neutropenia occurs</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr></tbody></table><p><b>Levomepromazine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i521.htm">Desferrioxamine</a></td><td>manufacturer of  levomepromazine advises avoid concomitant use with desferrioxamine </td><td></td></tr></tbody></table><p><b>Pericyazine</b> belongs to
      <b>Antipsychotics</b>
          but has no specific interaction information.
        </p><p><b>Perphenazine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i236.htm">Paroxetine</a></td><td>metabolism of  perphenazine inhibited by paroxetine (reduce dose of perphenazine)</td><td></td></tr></tbody></table><p><b>Pipotiazine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of depot formulation of  pipotiazine with clozapine as cannot be withdrawn quickly if neutropenia occurs</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr></tbody></table><p><b>Prochlorperazine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i521.htm">Desferrioxamine</a></td><td>avoidance of  prochlorperazine advised by manufacturer of desferrioxamine </td><td></td></tr></tbody></table><p><b>Promazine</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i628.htm">Suxamethonium</a></td><td> promazine possibly enhances effects of suxamethonium </td><td></td></tr></tbody></table><p><b>Trifluoperazine</b> belongs to
      <b>Antipsychotics</b>
          but has no specific interaction information.
        </p><p><b>Butyrophenones</b> belongs to
      <b>Antipsychotics</b>
          but has no specific interaction information.
        </p><p><b>Droperidol</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




















<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i809.htm">Amisulpride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with amisulpride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>manufacturer of  droperidol advises avoid concomitant use with tricyclics (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with chloroquine and hydroxychloroquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>manufacturer of  droperidol advises avoid concomitant use with fluoxetine (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>manufacturer of  droperidol advises avoid concomitant use with fluvoxamine (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i166.htm">Macrolides</a></td><td class="cBV"><b>manufacturer of  droperidol advises avoid concomitant use with macrolides (risk of ventricular arrhythmias)</b></td><td><i>See also</i> Telithromycin</td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with pentamidine isetionate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with phenothiazines that prolong the QT interval—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with quinine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td class="cBV"><b>manufacturer of  droperidol advises avoid concomitant use with sertraline (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i371.htm">Sulpiride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  droperidol given with sulpiride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b>manufacturer of  droperidol advises avoid concomitant use with tacrolimus (risk of ventricular arrhythmias)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i581.htm">Tamoxifen</a></td><td class="cBV"><b>manufacturer of  droperidol advises avoid concomitant use with tamoxifen (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i42.htm">Thiopental</a></td><td> droperidol enhances effects of thiopental </td><td></td></tr></tbody></table><p><b>Benperidol</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  benperidol given with amiodarone—manufacturer of benperidol advises avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  benperidol given with moxifloxacin—manufacturer of benperidol advises avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Haloperidol</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




























<tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td> haloperidol antagonises hypotensive effect of adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i406.htm">Alprazolam</a></td><td>plasma concentration of  haloperidol possibly increased by alprazolam </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  haloperidol given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>effects of  haloperidol possibly reduced by antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  haloperidol given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i427.htm">Buspirone</a></td><td>plasma concentration of  haloperidol increased by buspirone </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>metabolism of  haloperidol accelerated by carbamazepine (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i374.htm">Chlorpromazine</a></td><td>plasma concentration of  haloperidol possibly increased by chlorpromazine </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of depot formulation of  haloperidol with clozapine as cannot be withdrawn quickly if neutropenia occurs</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  haloperidol given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  haloperidol given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>plasma concentration of  haloperidol increased by fluoxetine </b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>plasma concentration of  haloperidol possibly increased by fluvoxamine </td><td></td></tr><tr><td><a href="41001i70.htm">Indometacin</a></td><td>possible severe drowsiness when  haloperidol given with indometacin </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>plasma concentration of  haloperidol possibly increased by itraconazole </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>increased risk of extrapyramidal side-effects and possibly neurotoxicity when  haloperidol given with lithium </td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  haloperidol given with mefloquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  haloperidol given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>metabolism of  haloperidol accelerated by phenobarbital (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  haloperidol reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  haloperidol given with quinine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  haloperidol accelerated by rifampicin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  haloperidol given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1034.htm">Sodium Benzoate</a></td><td> haloperidol possibly reduces effects of sodium benzoate </td><td></td></tr><tr><td><a href="41001i1033.htm">Sodium Phenylbutyrate</a></td><td> haloperidol possibly reduces effects of sodium phenylbutyrate </td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  haloperidol given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i371.htm">Sulpiride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  haloperidol given with sulpiride </b></td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td>plasma concentration of  haloperidol increased by venlafaxine </td><td></td></tr></tbody></table><p><b>Thioxanthenes</b> belongs to
      <b>Antipsychotics</b>
          but has no specific interaction information.
        </p><p><b>Flupentixol</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of depot formulation of  flupentixol with clozapine as cannot be withdrawn quickly if neutropenia occurs</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>increased risk of extrapyramidal side-effects and possibly neurotoxicity when  flupentixol given with lithium </td><td></td></tr></tbody></table><p><b>Zuclopenthixol</b> belongs to
      <b>Antipsychotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  zuclopenthixol given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of depot formulation of  zuclopenthixol with clozapine as cannot be withdrawn quickly if neutropenia occurs</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  zuclopenthixol given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  zuclopenthixol given with <i>parenteral</i> erythromycin—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>increased risk of extrapyramidal side-effects and possibly neurotoxicity when  zuclopenthixol given with lithium </td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  zuclopenthixol given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  zuclopenthixol given with sotalol—avoid concomitant use</b></td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1209.htm" title="Asenapine">Asenapine</a></li><li><a href="41001i1101.htm" title="Paliperidone">Paliperidone</a></li><li><a href="41001i1011.htm" title="Aripiprazole">Aripiprazole</a></li><li><a href="41001i809.htm" title="Amisulpride">Amisulpride</a></li><li><a href="41001i364.htm" title="Clozapine">Clozapine</a></li><li><a href="41001i366.htm" title="Olanzapine">Olanzapine</a></li><li><a href="41001i369.htm" title="Pimozide">Pimozide</a></li><li><a href="41001i824.htm" title="Quetiapine">Quetiapine</a></li><li><a href="41001i368.htm" title="Risperidone">Risperidone</a></li><li><a href="41001i371.htm" title="Sulpiride">Sulpiride</a></li><li id="_41001i373"><a href="41001i373.htm" title="Phenothiazines">Phenothiazines</a></li><li id="_41001i384"><a href="41001i384.htm" title="Butyrophenones">Butyrophenones</a></li><li id="_41001i388"><a href="41001i388.htm" title="Thioxanthenes">Thioxanthenes</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i916.htm">Previous: Trospium</a> | <a class="top" href="41001i363.htm#">Top</a> | <a accesskey="]" href="41001i1209.htm">Next: Asenapine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>